XERIS BIOPHARMA HOLDINGS, INC. Intangible Assets, Net (Excluding Goodwill)
XERIS BIOPHARMA HOLDINGS, INC. (XERS) had Intangible Assets, Net (Excluding Goodwill) of $82.66 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent › Intangible Asset, Excluding Goodwill, after Accumulated Amortization
us-gaap:IntangibleAssetsNetExcludingGoodwill · last filed 2026-08-06
- 2026-06-30: Intangible Assets, Net (Excluding Goodwill) $82.66M.
- 2026-03-31: Intangible Assets, Net (Excluding Goodwill) $85.37M.
- 2025-12-31: Intangible Assets, Net (Excluding Goodwill) $88.08M.
- 2025-09-30: Intangible Assets, Net (Excluding Goodwill) $90.79M.
| Period end | Intangible Assets, Net (Excluding Goodwill) |
|---|---|
| 2026-06-30 | $82.66M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $85.37M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $88.08M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $90.79M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $93.50M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $96.21M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $98.92M 10-K · filed 2026-03-02 |
| 2024-09-30 | $101.63M 10-Q · filed 2024-11-08 |
| 2024-06-30 | $104.34M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $107.05M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $109.76M 10-K · filed 2025-03-06 |
| 2023-09-30 | $112.47M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $115.19M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $117.90M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $120.61M 10-K · filed 2024-03-06 |
| 2022-09-30 | $123.32M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $126.03M 10-Q · filed 2022-08-10 |
| 2022-03-31 | $128.74M 10-Q · filed 2022-05-11 |
| 2021-12-31 | $131.45M 10-K · filed 2023-03-08 |
| 2020-12-31 | $0.00 10-K · filed 2022-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |